Bavarian Nordic’s share price fell by more than 17 percent on Friday in the wake of a disappointing account for the third quarter.
It is clear after the stock exchange closed. The share price has fallen by 17.43 percent to DKK 169.10.
In the third quarter of the year, the vaccine company had sales of DKK 1.36 billion.
Sales are roughly on par with the third quarter in 2023, but significantly less than what analysts had expected.
According to the financial media MarketWire, the analysts had predicted a turnover of DKK 1.62 billion.
The operating result is DKK 250 million, which is 34 percent less than the same period last year.
When the exchange closed on Friday, the C25 index also reached its lowest level so far this year. According to MarketWire, this is because the index fell by 1.2 percent on Friday.
The pharmaceutical companies Novo Nordisk and Zealand Pharma could also see their share prices take a dive on Friday.
According to Søren Løntoft Hansen, who is a stock analyst at Sydbank, it may be connected to the fact that the future president of the United States, Donald Trump, has nominated the vaccine skeptic Robert F. Kennedy Jr. to the Minister of Health.
– This is probably also something that the share reacts to. In any case, I note that there are other healthcare shares – in addition to Bavarian Nordic – that are also reacting negatively today, he says to Børsen.
Novo Nordisk fell by 5.4 percent to DKK 711, with Zealand Pharma falling by 10.1 percent to DKK 720.5.
Kennedy must first be approved by the Senate, but the news that he may be at the helm of the American healthcare system may have created nervousness around the Danish pharmaceutical shares.
This is the opinion of Jyske Bank’s senior equity advisor Martin Munk to MarketWire.
/ritzau/
Source: www.kristeligt-dagblad.dk
